HudsonAlpha’s Devin Absher, PhD, and David Bick, MD, sat down with Clinical OMICs magazine to discuss the use of next-generation sequencing (NGS) for the identification and treatment of rare diseases and cancer.
“We are rapidly reaching the point where we do whole genome sequencing on anybody you think has a rare disease,” said Bick.
Many in the industry recognize that NGS technology has matured and generating sequencing data is becoming standard practice.
“I don’t think the technology is the issue anymore. It has become fairly standardized and routine,” said Absher. “So it’s really how you take the data, integrate it, and provide the clinical decision support for that oncologist who may not have a lot of experience with sequencing data.”
Read the full story on page 26.